1 / 8

New Treatments for T2DM

New Treatments for T2DM. By:Dina Palmer Advisor: Robert Hadley Ph.D., PA-C . The doom of T2DM. 20.8 million Americans with diabetes 54 million with pre-diabetes Rise in all age groups due to aging of our population, increased obesity, and sedentary lifestyles

keala
Download Presentation

New Treatments for T2DM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Treatments for T2DM By:Dina Palmer Advisor: Robert Hadley Ph.D., PA-C

  2. The doom of T2DM • 20.8 million Americans with diabetes • 54 million with pre-diabetes • Rise in all age groups due to aging of our population, increased obesity, and sedentary lifestyles • Glycemic control of 7% A1C or less • These are our patients !

  3. Old and new drugs… • Combination therapy • Favorites: metformin, sulfonylureas, thiazolidinediones • New classes… • -DPP4 inhibitors: Sitagliptin (Januvia) and Vildagliptin (Galvus) • -GLP-1 agonists: Exenatide (Byetta) and Liraglutide • -Glitazars: Muraglitazar (Pargluva)

  4. DPP4 inhibitors • Sitagliptin (Januvia) and Vildagliptin (Galvus) • Incretins are hormones released by the GI tract in response to nutrient ingestion that stimulate beta cells to secrete insulin—these effects are diminished in T2DM • DPP4 is a protease that breaks down the endogenous incretin glucagon-like peptide (GLP)-1 • This class prevents the degradation of GLP-1 by competitively and reversibly inhibiting the protease DPP4, and leads to longer presence and actions of GLP-1 • SE: No weight gain! rare hypoglycemia. • Both to be used as a combination, both oral. Sitagliptin approved Fall 2006, Vildagliptin awaiting approval.

  5. GLP-1 agonists • Exenatide (Byetta) and Liraglutide • Exogenous GLP-1 products that are resistant to DPP4 degradation, same actions as the endogenous incretin. • Also known as incretin mimetics. • Exenatide a 2xd inj. approved 2005 for use with metformin and/or a sulfonylurea. SE: n/v/diar, hypoglyc (esp with sulfas), w. loss. Contra: GI dz, renal Cr <30mL/min. Current trials for once weekly injection. • Liraglutide is awaiting approval. Has longer half life than Byetta thus only requiring once daily injections. Same SE, no contraindications identified yet.

  6. Glitazars • Muraglitazar (Pargluva) • Approved by FDA, then withdrawn in Spring 2006. Other trials in this category are in progress. • Glitazars activate two subtypes of receptors called peroxisome proliferator–activated receptors (PPARs). • PPARgamma activation reduces insulin resistance and improves glycemic control, while activation of PPARalpha reduces triglycerides and increases HDL concentration by increasing fatty acid oxidation. • Oral dose. SE: w. gain, edema, low incidence of coronary and cerebral vascular events, possible congestive heart failure-FDA decided it was of enough significance.

  7. To sum up… • T2DM is growing. • Glycemic control is essential for preventing the microvascular complications of this disease including retinal, glomerular, and nerve changes, and for preventing diabetes progression. • Current treatments don’t always maintain glycemic control and some have unfavorable side effects (esp weight gain).

  8. References: • Ahrén B, Gomis R, Standl E, Mills D, Schweizer A.Twelve- and 52-week efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-treated patients with type 2 diabetes. Diabetes Care 27(12):2874-2880, 2004. • Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care.  2005;28(8):1936-1940. • ADA. StandardsofMedicalCareinDiabetes–2006. DiabetesCare2006;29:S4-S42. • ADA. Standards of Medical Care in Diabetes-2007. Diabetes Care 2007:30:S4-41S. • ADA Total prevalence of diabetes and pre-diabetes. www.diabetes.org • Baggio LL, Drucker DJ . American Diabetes Association’s 66th Annual Scientific Sessions-Incretin-Based Therapies- Incretin analogs other than Exenatide. Medscape Diabetes & Endocrinology, Jul 25 2006. URL: http://www.medscape.com/viewarticle/540919, Accessed 11/29/06. • Baggio LL, Drucker DJ.Incretin Hormones in the Treatment of Type 2 Diabetes: Therapeutic Applications of DPP-IV Inhibitors.Medscape Diabetes & Endocrinology. Apr 2006. URL: http://www.medscape.com/viewarticle/530215, Accessed 11/20/06. • Brophy JM. Selling safety—lessons from muraglitazar. JAMA. 2005;294:2633-2635. • Cara JF. Type 2 diabetes mellitus in children. 2000 American Academy of Pediatrics Annual Meeting. Nov 2000. Medscape conference coverage. URL: http://www.medscape.com/viewarticle/420203, Accessed 12/2/06. • Craig CR, Stitzel RE. Modern Pharmacology with Clinical Applications. Lippincott Williams and Wilkins, 2004: 763-776. • Conlon D. Goodbye glitazars?. Br J Diabetes Vasc Dis.  2006;6(3):135-137. • Dale DC, Federman DD, Antman K, Atkinson JP, Cassel CK, Feldman M, et al. ACP medicine textbook. WebMD publishing, 2006: 615-649. • FDA approved drug products. www.fda.gov. • Gavin JR, Conner CS, Drucker DJ, Kahn SE. The clinical impact of incretin-based therapies on type 2 diabetes management, one year later. From the American Diabetes Association’s 66th Annual Scientific Sessions. Consensus medical communications. June 9, 2006. • Hansotia T, Drucker DJ. Therapeutic potential of the DPP-IV inhibitors. 65th Scientific Sessions of the American Diabetes Association. Medscape Diabetes & Endocrinology, Jul 2005. URL: http://www.medscape.com/viewarticle/508221, Accessed 11/29/06. • Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, MD, Fineman MS, et al.  Effects of Exenatide on glycemic control over 30 weeks in patients with type 2 diabetes treated with Metformin and a Sulfonylurea. Diabetes Care 2005;28 (5): 1083-1091. • Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care.  2006;29(5):1016-1023. • Merck & Co. Prescribing information. www.januvia.com. Merck & Co. 2006. • Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581-2586. • Peters AL. American Diabetes Association’s 66th Annual Scientific Sessions-Incretin-Based Therapies-Exenatide. Medscape Diabetes & Endocrinology, Jul 25 2006. URL: http://www.medscape.com/viewarticle/540917, Accessed 11/29/06. • Retnakaran R, Drucker DJ. American Diabetes Association’s 66th Annual Scientific Sessions-Incretin-Based Therapies-DPP-IV Inhibitors. Medscape Diabetes & Endocrinology, Jul 25 2006. URL: http://www.medscape.com/viewarticle/540920, Accessed 10/31/06. • Riddle MC, Drucker DJ.Emerging therapies mimicking the effects of Amylin and Glucagon-Like Peptide 1. Diabetes Care.  2006;29(2):435-449. • Triplitt C, Chiquette E.Exenatide: from the Gila Monster to the pharmacy. J Am Pharm Assoc.  2006;46(1):44-55. • Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy Publications, 2006;26(3):360-374.

More Related